We conducted a cross-sectional analysis to determine HIV virologic failure and its associated factors among Omani people living with HIV who are on ART for > 6 months. Patients (n = 1427) were identified from a central national HIV surveillance dataset. Two-thirds (67%) of patients were male, and the median age was 39 years (IQR, 32-48 years). Out of 1427 patients, 14.4% had virologic failure (HIV viral load [VL] ≥ 200 copies/ml). The multivariate analysis showed that patients aged 25-49 years (adjusted odds ratio [aOR]: 1.76, 95% CI: 1.01-3.08) were significantly more likely to fail treatment, compared to those aged ≥ 50 years. Besides, having “Other” HIV risk factor (compared to heterosexuals, aOR: 1.82, 95% CI: 1.02-3.24) and receiving HIV care outside the capital Muscat (compared to those cared for in Muscat, aOR: 1.73, 95% CI: 1.11-2.7) were independently associated with virologic failure. HIV viral suppression (85.6%) in Oman is encouraging; however, further strategies, mainly targeting patients who are young (<50 years), those not disclosing their HIV risk factor and those attending HIV treatment centres outside Muscat, are required to enhance HIV treatment outcome in Oman.
Department of Health and Human Services. Panel on antiretroviral guidelines for adults and adolescents guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents,https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/0 (2019, accessed 15 May 2020).
2.
Jensen-FangelSPedersenLPedersenC, et al. Low mortality in HIV-infected patients starting highly active antiretroviral therapy: a comparison with the general population. AIDS2004; 18: 89–97.
3.
RodgerAJCambianoVBruunT, et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA2016; 316: 171–181.
4.
HatanoHHuntPWeidlerJ, et al. Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-Infected patients who continue to receive a stable, partially suppressive treatment regimen. Clin Infect Dis2006; 43: 1329–1336.
5.
PetersenMLvan der LaanMJNapravnikS, et al. Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS2008; 22: 2097–2106.
6.
LiZPurcellDWSansomSL, et al. Vital signs: HIV transmission along the continuum of care – United States, 2016. MMWR Morb Mortal Wkly Rep2019; 68: 267–272.
7.
BonnerKMezochowARobertsT, et al. Viral load monitoring as a tool to reinforce adherence: a systematic review. J Acquir Immune Defic Syndr2013; 64: 74–78.
8.
WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2nd ed. Geneva: World Health Organization, 2016.
9.
AmirkhanianYAKellyJADiFranceiscoWJ, et al. Predictors of HIV care engagement, antiretroviral medication adherence, and viral suppression among people living with HIV infection in St. Petersburg, Russia. AIDS Behav2018; 22: 791–799.
10.
RangarajanSDonnJCGiangLT, et al. Factors associated with HIV viral load suppression on antiretroviral therapy in Vietnam. J Virus Erad2016; 2: 94–101.
11.
BulageLSsewanyanaINankabirwaV, et al. Factors associated with virological non-suppression among HIV-positive patients on antiretroviral therapy in Uganda, August 2014–July 2015. BMC Infect Dis2017; 17: 326.
12.
FloridiaMGiulianoMPalmisanoL, et al. Gender differences in the treatment of HIV infection. Pharmacol Res2008; 58: 173–182.
13.
BeattieCMWiewelEWZhongY, et al. Multilevel factors associated with a lack of viral suppression among persons living with HIV in a federally funded housing program. AIDS Behav2019; 23: 784–791.
14.
Jean LouisFButeauJFrançoisK, et al. Virologic outcome among patients receiving antiretroviral therapy at five hospitals in Haiti. PLoS One2018; 13: e0192077.
15.
KiweewaFEsberAMusingyeE, et al. HIV virologic failure and its predictors among HIV-infected adults on antiretroviral therapy in the African cohort study. PLoS One2019; 14: e0211344.
16.
HichamTIlyasETarikH, et al. Risk factors associated with unsuppressed viral load in HIV-1 infected patients at the first antiretroviral therapy in Morocco. Int J Mycobacteriol2019; 8: 113–117.
17.
DatayMIBoulleAMantD, et al. Associations with virologic treatment failure in adults on antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr2010; 54: 489–495.
18.
MaYZhaoDYuL, et al. Predictors of virologic failure in HIV-1- infected adults receiving first-line antiretroviral therapy in eight provinces in China. Clin Infect Dis2010; 50: 264–271.
19.
ElgalibAShahSAl-HabsiZ, et al. HIV viral suppression in Oman: encouraging progress toward achieving the united nations ‘third 90’. Int J Infect Dis2018; 71: 94–99.
20.
ElgalibAAl-SawafiHKambleB, et al. Multidisciplinary care model for HIV improves treatment outcome: a single-centre experience from the Middle East. AIDS Care2018; 30: 1114–1119.
ElgalibAShahSAl-HabsiZ, et al. The Cascade of HIV care in Oman, 2015–2018: a population-based study from the Middle East. Int J Infect Dis2020; 90: 28–34.
23.
SheehanDMDawitRGbadamosiSO, et al. Sustained HIV viral suppression among men who have sex with men in the Miami-Dade County Ryan White Program: the effect of demographic, psychosocial, provider and neighborhood factors. BMC Public Health2020; 20: 326.
24.
BradleyHMattsonCLBeerL, et al. Increased antiretroviral therapy prescription and HIV viral suppression among persons receiving clinical care for HIV infection. AIDS2016; 30: 2117–2124.
25.
GriffithDSnyderJDellS, et al. Impact of a youth-focused care model on retention and virologic suppression among young adults with HIV cared for in an adult HIV clinic. J Acquir Immune Defic Syndr2019; 80: e41–e47.
26.
GhideiLSimoneMJSalowMJ, et al. Aging, antiretrovirals, and adherence: a meta-analysis of adherence among older HIV-infected individuals. Drugs Aging2013; 30: 809–819.
27.
EmletCA.A comparison of HIV stigma and disclosure patterns between older and younger adults living with HIV/AIDS. AIDS Patient Care STDS2006; 20: 350–358.
28.
SilverbergMJLeydenWHorbergMA, et al. Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med2007; 167: 684–691.
29.
KatzITRyuAEOnuegbuAG, et al. Impact of HIV-related stigma on treatment adherence: systematic review and meta-synthesis. J Int AIDS Soc2013; 16: 18640.
30.
DowshenNBinnsHJGarofaloR.Experiences of HIV-related stigma among young men who have sex with men. AIDS Patient Care STDS2009; 23: 371–376.
ElgalibAShahSAl-WahaibiA, et al. The epidemiology of HIV in Oman, 1984–2018: a nationwide study from the Middle East. J Epidemiol Global Health. 2020; 10: 222–229.
33.
AmankwaaIBoatengDQuansahDY, et al. Effectiveness of short message services and voice call interventions for antiretroviral therapy adherence and other outcomes: a systematic review and meta-analysis. PLoS One2018; 13: e0204091.
